

MSc Neuromuscular Disease

View Online



[1]

D. Blottner and M. Salanova, The neuromuscular system: from earth to space life science : neuromuscular cell signalling in disuse and exercise, vol. Springer briefs in space life sciences. Cham: Springer, 2015. Available:
<http://UCL.ebib.com/patron/FullRecord.aspx?p=1967380>

[2]

M. K. D. Benson, Children's neuromuscular disorders. London: Springer, 2011.

[3]

A. Shaibani, A Video Atlas of Neuromuscular Disorders. Oxford University Press, 2014. doi: 10.1093/med/9780199898152.001.0001. Available:
<http://www.oxfordmedicine.com/view/10.1093/med/9780199898152.001.0001/med-9780199898152>

[4]

D. Hilton-Jones and M. R. Turner, Eds, Oxford textbook of neuromuscular disorders, vol. Oxford textbooks in clinical neurology. [Oxford]: Oxford University Press, 2014. Available:
<http://dx.doi.org/10.1093/med/9780199698073.001.0001>

[5]

D. Kernell, The Motoneurone and its Muscle Fibres. Oxford University Press, 2006. doi: 10.1093/acprof:oso/9780198526551.001.0001. Available:
<http://www.oxfordscholarship.com/view/10.1093/acprof:oso/9780198526551.001.0001/acprof-9780198526551>

[6]

A. A. Amato and J. A. Russell, *Neuromuscular disorders*. New York: McGraw-Hill, 2008.

[7]

K. K. Jain, Ed., *Applied neurogenomics*, vol. *Neuromethods*. New York, NY: Humana Press, 2015. Available: <http://dx.doi.org/10.1007/978-1-4939-2247-5>

[8]

A. M. Davies, 'Regulation of Neuronal Survival by Neurotrophins in the Developing Peripheral Nervous System', in *Patterning and Cell Type Specification in the Developing CNS and PNS*, Elsevier, 2013, pp. 303–311. doi: 10.1016/B978-0-12-397265-1.00095-2. Available: <http://linkinghub.elsevier.com/retrieve/pii/B9780123972651000952>

[9]

T. Gordon and O. A. Sulaiman, 'Nerve Regeneration in the Peripheral Nervous System', in *Neuroglia*, H. Kettenmann, Ed., Oxford University Press, 2012, pp. 701–714. doi: 10.1093/med/9780199794591.003.0055. Available: <http://www.oxfordmedicine.com/view/10.1093/med/9780199794591.001.0001/med-9780199794591-chapter-55>

[10]

M. B. Welch and C. M. Brummett, 'Peripheral Nervous System Anatomy and Function', in *Neuroscientific Foundations of Anesthesiology*, G. A. Mashour and R. Lydic, Eds, Oxford University Press, 2011, pp. 133–140. doi: 10.1093/med/9780195398243.003.0067. Available: <http://oxfordmedicine.com/view/10.1093/med/9780195398243.001.0001/med-9780195398243-chapter-010>

[11]

A. M. Rossor, P. J. Tomaselli, and M. M. Reilly, 'Recent advances in the genetic neuropathies', *Current Opinion in Neurology*, Sept. 2016, doi: 10.1097/WCO.0000000000000373

[12]

A. M. Rossor, M. R. B. Evans, and M. M. Reilly, 'A practical approach to the genetic neuropathies', *Practical Neurology*, vol. 15, no. 3, pp. 187–198, June 2015, doi: 10.1136/practneurol-2015-001095

[13]

AM Rossor, 'Recent advances in the genetic neuropathies', *Current opinion in neurology*, vol. 29, no. 5, 2016, doi: 10.1097/WCO.0000000000000373. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130159/>

[14]

M. Reilly and V. Fridman, 'Inherited Neuropathies', *Seminars in Neurology*, vol. 35, no. 04, pp. 407–423, Oct. 2015, doi: 10.1055/s-0035-1558981

[15]

A. M. Rossor, M. R. B. Evans, and M. M. Reilly, 'A practical approach to the genetic neuropathies', *Practical Neurology*, vol. 15, no. 3, pp. 187–198, June 2015, doi: 10.1136/practneurol-2015-001095

[16]

R. J. Pasterkamp, 'Getting neural circuits into shape with semaphorins', *Nature Reviews Neuroscience*, vol. 13, no. 9, pp. 605–618, Aug. 2012, doi: 10.1038/nrn3302

[17]

R Klein, 'Role of neurotrophins in mouse neuronal development.', *The FASEB Journal*, vol. 8, no. 10, pp. 738–744, 1994, Available: <http://www.fasebj.org/content/8/10/738.long>

[18]

G. Schlosser, 'Induction and specification of cranial placodes', *Developmental Biology*, vol. 294, no. 2, pp. 303–351, June 2006, doi: 10.1016/j.ydbio.2006.03.009

[19]

N. K. Thiede-Stan and M. E. Schwab, 'Attractive and repulsive factors act through multi-subunit receptor complexes to regulate nerve fiber growth', *Journal of Cell Science*, vol. 128, no. 14, pp. 2403–2414, July 2015, doi: 10.1242/jcs.165555

[20]

Irina Dudanova, 'Genetic Evidence for a Contribution of EphA:EphrinA Reverse Signaling to Motor Axon Guidance', *Journal of Neuroscience*, vol. 32, no. 15, pp. 5209–5215, 2012, Available: <http://www.jneurosci.org/content/32/15/5209>

[21]

L. Wang, R. Klein, B. Zheng, and T. Marquardt, 'Anatomical Coupling of Sensory and Motor Nerve Trajectory via Axon Tracking', *Neuron*, vol. 71, no. 2, pp. 263–277, July 2011, doi: 10.1016/j.neuron.2011.06.021

[22]

E. Y. Van Battum, S. Brignani, and R. J. Pasterkamp, 'Axon guidance proteins in neurological disorders', *The Lancet Neurology*, vol. 14, no. 5, pp. 532–546, May 2015, doi: 10.1016/S1474-4422(14)70257-1

[23]

T.-J. Kao, C. Law, and A. Kania, 'Eph and ephrin signaling: Lessons learned from spinal motor neurons', *Seminars in Cell & Developmental Biology*, vol. 23, no. 1, pp. 83–91, Feb. 2012, doi: 10.1016/j.semcdb.2011.10.016

[24]

Byung-Yong Park, 'Induction and Segregation of the Vertebrate Cranial Placodes', 2010, Available: <https://www.ncbi.nlm.nih.gov/books/NBK53175/>

[25]

M. Taniguchi et al., 'Disruption of Semaphorin III/D Gene Causes Severe Abnormality in Peripheral Nerve Projection', *Neuron*, vol. 19, no. 3, pp. 519–530, Sept. 1997, doi: 10.1016/S0896-6273(00)80368-2

[26]

A. Ebens et al., 'Hepatocyte Growth Factor/Scatter Factor Is an Axonal Chemoattractant and a Neurotrophic Factor for Spinal Motor Neurons', *Neuron*, vol. 17, no. 6, pp. 1157–1172, Dec. 1996, doi: 10.1016/S0896-6273(00)80247-0

[27]

A. Caton, 'The branchial arches and HGF are growth-promoting and chemoattractant for cranial motor axons', *Development*, vol. 127, no. 8, pp. 1751–1766, Available: <http://dev.biologists.org/content/127/8/1751.long>

[28]

J. C. Conover et al., 'Neuronal deficits, not involving motor neurons, in mice lacking BDNF and/or NT4', *Nature*, vol. 375, no. 6528, pp. 235–238, May 1995, doi: 10.1038/375235a0

[29]

K. R. Jessen and R. Mirsky, 'The origin and development of glial cells in peripheral nerves', *Nature Reviews Neuroscience*, vol. 6, no. 9, pp. 671–682, Sept. 2005, doi: 10.1038/nrn1746

[30]

K. R. Monk, M. L. Feltri, and C. Taveggia, 'New insights on schwann cell development', *Glia*, vol. 63, no. 8, pp. 1376–1393, Aug. 2015, doi: 10.1002/glia.22852

[31]

K. R. Jessen, R. Mirsky, and A. C. Lloyd, 'Schwann Cells: Development and Role in Nerve Repair', *Cold Spring Harbor Perspectives in Biology*, vol. 7, no. 7, July 2015, doi: 10.1101/cshperspect.a020487

[32]

J. L. Salzer, 'Schwann Cell Myelination', *Cold Spring Harbor Perspectives in Biology*, vol. 7,

no. 8, Aug. 2015, doi: 10.1101/cshperspect.a020529

[33]

P. J. Arthur-Farraj et al., 'c-Jun Reprograms Schwann Cells of Injured Nerves to Generate a Repair Cell Essential for Regeneration', *Neuron*, vol. 75, no. 4, pp. 633–647, Aug. 2012, doi: 10.1016/j.neuron.2012.06.021

[34]

A. Brosius Lutz and B. A. Barres, 'Contrasting the Glial Response to Axon Injury in the Central and Peripheral Nervous Systems', *Developmental Cell*, vol. 28, no. 1, pp. 7–17, Jan. 2014, doi: 10.1016/j.devcel.2013.12.002

[35]

K. R. Jessen and R. Mirsky, 'The repair Schwann cell and its function in regenerating nerves', *The Journal of Physiology*, vol. 594, no. 13, pp. 3521–3531, July 2016, doi: 10.1113/JP270874

[36]

M. Auer-Grumbach, 'Hereditary sensory and autonomic neuropathies', in *Peripheral Nerve Disorders*, Elsevier, 2013, pp. 893–906. doi: 10.1016/B978-0-444-52902-2.00050-3. Available: <http://linkinghub.elsevier.com/retrieve/pii/B9780444529022000503>

[37]

G. L. Davidson et al., 'Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort', *Journal of Neurology*, vol. 259, no. 8, pp. 1673–1685, Aug. 2012, doi: 10.1007/s00415-011-6397-y

[38]

A. M. Rossor, M. R. B. Evans, and M. M. Reilly, 'A practical approach to the genetic neuropathies', *Practical Neurology*, vol. 15, no. 3, pp. 187–198, June 2015, doi: 10.1136/practneurol-2015-001095

[39]

A. Chhabra, 'Peripheral MR Neurography', *Neuroimaging Clinics of North America*, vol. 24, no. 1, pp. 79–89, Feb. 2014, doi: 10.1016/j.nic.2013.03.033

[40]

D. Purves, *Neuroscience*. Bethesda: National Library of Medicine, 2001. Available: <http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View..ShowTOC&rid=neurosci.TOC&depth=2>

[41]

'Effects of axon diameter and myelination (video) | Khan Academy'. Available: <https://www.khanacademy.org/science/health-and-medicine/nervous-system-and-sensory-innervation/neuron-membrane-potentials-2014-03-27T17:58:17.207Z/v/effects-of-axon-diameter-and-myelination>

[42]

'Nerve Signaling'. Available: https://www.nobelprize.org/educational/medicine/nerve_signaling/index.html

[43]

J. S. Duncan, G. P. Winston, M. J. Koepp, and S. Ourselin, 'Brain imaging in the assessment for epilepsy surgery', *The Lancet Neurology*, vol. 15, no. 4, pp. 420–433, Apr. 2016, doi: 10.1016/S1474-4422(15)00383-X

[44]

M. Nowell et al., 'Resection planning in extratemporal epilepsy surgery using 3D multimodality imaging and intraoperative MRI', *British Journal of Neurosurgery*, vol. 31, no. 4, pp. 468–470, July 2017, doi: 10.1080/02688697.2016.1265086

[45]

V. N. Vakharia et al., 'Accuracy of intracranial electrode placement for stereoelectroencephalography: A systematic review and meta-analysis', *Epilepsia*, vol. 58, no. 6, pp. 921–932, June 2017, doi: 10.1111/epi.13713

[46]

A. Michell, Understanding EMG. Oxford University Press, 2013. doi: 10.1093/med/9780199595501.001.0001. Available: <http://oxfordmedicine.com/view/10.1093/med/9780199595501.001.0001/med-9780199595501>

[47]

D. C. Preston and B. E. Shapiro, Electromyography and neuromuscular disorders: clinical-electrophysiologic correlations, 3rd ed. London: Elsevier Saunders, 2013.

[48]

'Top tips for writing a lay summary | The Academy of Medical Sciences'. Available: <https://acmedsci.ac.uk/more/news/10-tips-for-writing-a-lay-summary>

[49]

'How to Write a Lay Summary | Digital Curation Centre'. Available: <http://www.dcc.ac.uk/resources/how-guides/write-lay-summary>

[50]

'Free guides'. Available: <http://www.plainenglish.co.uk/free-guides.html>

[51]

'Part two - The specifics - Access to Understanding'. Available: <http://www.access2understanding.org/guidance/part-two-the-specifics/>

[52]

'Readable | Free Readability Test Tool'. Available: <https://www.webpagefx.com/tools/read-able/>

[53]

J. H. Rees, 'Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage', *Journal of Neurology, Neurosurgery & Psychiatry*, vol. 75, no. suppl_2, pp. ii43-ii50, June 2004, doi: 10.1136/jnnp.2004.040378

[54]

J.-C. Antoine and J.-P. Camdessanché, 'Paraneoplastic disorders of the peripheral nervous system', *La Presse Médicale*, vol. 42, no. 6, pp. e235-e244, June 2013, doi: 10.1016/j.lpm.2013.01.059

[55]

'How to Write a Lay Summary | DCC How-to Guides'. Available: <http://www.dcc.ac.uk/resources/how-guides/>

[56]

A. M. Rossor, M. R. B. Evans, and M. M. Reilly, 'A practical approach to the genetic neuropathies', *Practical Neurology*, vol. 15, no. 3, pp. 187-198, June 2015, doi: 10.1136/practneurol-2015-001095

[57]

A. M. Rossor, B. Kalmar, L. Greensmith, and M. M. Reilly, 'The distal hereditary motor neuropathies', *Journal of Neurology, Neurosurgery & Psychiatry*, vol. 83, no. 1, pp. 6-14, Jan. 2012, doi: 10.1136/jnnp-2011-300952

[58]

A. M. Rossor et al., 'Peripheral neuropathy in complex inherited diseases: an approach to diagnosis', *Journal of Neurology, Neurosurgery & Psychiatry*, vol. 88, no. 10, pp. 846-863, Oct. 2017, doi: 10.1136/jnnp-2016-313960

[59]

A. S. Carr et al., 'A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK', *Journal of Neurology, Neurosurgery & Psychiatry*, vol. 87, no. 6, pp. 620-627, June 2016, doi: 10.1136/jnnp-2015-310907

[60]

P. N. Hawkins, Y. Ando, A. Dispenzeri, A. Gonzalez-Duarte, D. Adams, and O. B. Suhr, 'Evolving landscape in the management of transthyretin amyloidosis', *Annals of Medicine*, vol. 47, no. 8, pp. 625–638, Nov. 2015, doi: 10.3109/07853890.2015.1068949

[61]

V. Plante-Bordeneuve et al., 'Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)', *Neurology*, vol. 69, no. 7, pp. 693–698, Aug. 2007, doi: 10.1212/01.wnl.0000267338.45673.f4

[62]

S. Dubrey, E. Ackermann, and J. Gillmore, 'The transthyretin amyloidoses: advances in therapy', *Postgraduate Medical Journal*, vol. 91, no. 1078, pp. 439–448, Aug. 2015, doi: 10.1136/postgradmedj-2014-133224

[63]

M. M. Dimachkie and R. J. Barohn, 'Guillain-Barré Syndrome and Variants', *Neurologic Clinics*, vol. 31, no. 2, pp. 491–510, May 2013, doi: 10.1016/j.ncl.2013.01.005

[64]

H. J. Willison, B. C. Jacobs, and P. A. van Doorn, 'Guillain-Barré syndrome', *The Lancet*, vol. 388, no. 10045, pp. 717–727, Aug. 2016, doi: 10.1016/S0140-6736(16)00339-1

[65]

M. P. Collins and R. D. Hadden, 'The nonsystemic vasculitic neuropathies', *Nature Reviews Neurology*, vol. 13, no. 5, pp. 302–316, Apr. 2017, doi: 10.1038/nrneurol.2017.42

[66]

M. Yates et al., 'EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis', *Annals of the Rheumatic Diseases*, vol. 75, no. 9, pp. 1583–1594, Sept. 2016, doi: 10.1136/annrheumdis-2016-209133

[67]

M. P. Collins et al., 'Peripheral Nerve Society Guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary', *Journal of the Peripheral Nervous System*, vol. 15, no. 3, pp. 176–184, Sept. 2010, doi: 10.1111/j.1529-8027.2010.00281.x

[68]

M. P. Berthelsen, E. Husu, S. B. Christensen, K. P. Prahm, J. Vissing, and B. R. Jensen, 'Anti-gravity training improves walking capacity and postural balance in patients with muscular dystrophy', *Neuromuscular Disorders*, vol. 24, no. 6, pp. 492–498, June 2014, doi: 10.1016/j.nmd.2014.03.001

[69]

E. H. Cup et al., 'Exercise Therapy and Other Types of Physical Therapy for Patients With Neuromuscular Diseases: A Systematic Review', *Archives of Physical Medicine and Rehabilitation*, vol. 88, no. 11, pp. 1452–1464, Nov. 2007, doi: 10.1016/j.apmr.2007.07.024

[70]

'Strength training and aerobic exercise training for muscle disease - van der Kooi - 2005 - The Cochrane Library - Wiley Online Library', Available: <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003907.pub2/abstract?systemMessage=Wiley+Online+Library+usage+report+download+page+will+be+unavailable+on+Friday+24th+November+2017+at+21%3A00+EST+%2F+02.00+GMT+%2F+10%3A00+SGT+%28Saturday+25th+Nov+for+SGT+>

[71]

M.-L. Sveen et al., 'Resistance training in patients with limb-girdle and becker muscular dystrophies', *Muscle & Nerve*, vol. 47, no. 2, pp. 163–169, Feb. 2013, doi: 10.1002/mus.23491

[72]

T. D. Jeppesen et al., 'Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy', *Brain*, vol. 129, no. 12, pp. 3402–3412, June 2006, doi:

10.1093/brain/awl149

[73]

'Balance and walking involvement in facioscapulohumeral dystrophy: a pilot study on the effects of custom lower limb orthoses - European Journal of Physical and Rehabilitation Medicine 2013 April;49(2):169-78 - Minerva Medica - Journals'. Available: <https://www.minervamedica.it/en/journals/europa-medicophysica/article.php?cod=R33Y2013N02A0169>

[74]

Michael P. Wiggs, 'Can endurance exercise preconditioning prevention disuse muscle atrophy?', *Frontiers in Physiology*, vol. 6, 2015, doi: 10.3389/fphys.2015.00063. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356230/>

[75]

Keith Baar, 'Using Molecular Biology to Maximize Concurrent Training', *Sports Medicine (Auckland, N.z.)*, vol. 44, no. Suppl 2, 2014, doi: 10.1007/s40279-014-0252-0. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213370/>

[76]

D. M. Craig et al., 'Utilizing small nutrient compounds as enhancers of exercise-induced mitochondrial biogenesis', *Frontiers in Physiology*, vol. 6, Oct. 2015, doi: 10.3389/fphys.2015.00296

[77]

B. Hoier and Y. Hellsten, 'Exercise-Induced Capillary Growth in Human Skeletal Muscle and the Dynamics of VEGF', *Microcirculation*, vol. 21, no. 4, pp. 301-314, May 2014, doi: 10.1111/micc.12117

[78]

D. G. Hardie, 'AMPK: A Key Sensor of Fuel and Energy Status in Skeletal Muscle', *Physiology*, vol. 21, no. 1, pp. 48-60, Feb. 2006, doi: 10.1152/physiol.00044.2005

[79]

J. A. Hawley, M. Hargreaves, M. J. Joyner, and J. R. Zierath, 'Integrative Biology of Exercise', *Cell*, vol. 159, no. 4, pp. 738–749, Nov. 2014, doi: 10.1016/j.cell.2014.10.029

[80]

D. A. Jones, A. de Haan, and J. M. Round, *Skeletal muscle from molecules to movement: a textbook of muscle physiology for sport, exercise, physiotherapy and medicine*. Edinburgh: Churchill Livingstone, 2004.

[81]

A. M. Gordon, 'Regulation of Contraction in Striated Muscle', *Physiological Reviews*, vol. 80, no. 2, pp. 853–924, Jan. 2000, Available: <http://physrev.physiology.org/content/80/2/853.long>

[82]

R Bottinelli, 'Force-velocity properties of human skeletal muscle fibres: myosin heavy chain isoform and temperature dependence.', *The Journal of Physiology*, vol. 495, no. Pt 2, 1996, Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1160815/>

[83]

S. D. R. Harridge et al., 'Whole-muscle and single-fibre contractile properties and myosin heavy chain isoforms in humans', *Pflügers Archiv - European Journal of Physiology*, vol. 432, no. 5, pp. 913–920, Sept. 1996, doi: 10.1007/s004240050215

[84]

By: Hunter, S (Hunter, S); White, M (White, M); Thompson, M (Thompson, M), 'Techniques to evaluate elderly human muscle function: A physiological basis', *JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES* *JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES*, vol. 53, no. 3, 1998, Available: https://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=6&SID=E3HXcKOaUmhvHimfaQi&page=1&doc=1

[85]

T. D. O'Brien, N. D. Reeves, V. Baltzopoulos, D. A. Jones, and C. N. Maganaris, 'In vivo measurements of muscle specific tension in adults and children', *Experimental Physiology*, vol. 95, no. 1, pp. 202–210, Jan. 2010, doi: 10.1113/expphysiol.2009.048967

[86]

C. Clarke, R. Howard, M. Rossor, S. D. Shorvon, National Hospital for Neurology and Neurosurgery (London, England), and Institute of Neurology, Queen Square, Neurology: a Queen Square textbook. Chichester: Wiley-Blackwell, 2009. Available: <http://onlinelibrary.wiley.com/book/10.1002/9781444311709>

[87]

'Neuromuscular Disease Centre'. Available: <http://neuromuscular.wustl.edu/>

[88]

Richard J. Barohn, 'A PATTERN RECOGNITION APPROACH TO THE PATIENT WITH A SUSPECTED MYOPATHY', *Neurologic clinics*, vol. 32, no. 3, 2014, doi: 10.1016/j.ncl.2014.04.008. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233647/>

[89]

M. P. Wattjes, R. A. Kley, and D. Fischer, 'Neuromuscular imaging in inherited muscle diseases', *European Radiology*, vol. 20, no. 10, pp. 2447–2460, Oct. 2010, doi: 10.1007/s00330-010-1799-2

[90]

J. M. Morrow et al., 'MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study', *The Lancet Neurology*, vol. 15, no. 1, pp. 65–77, Jan. 2016, doi: 10.1016/S1474-4422(15)00242-2

[91]

D. Briggs and J. E. Morgan, 'Recent progress in satellite cell/myoblast engraftment - relevance for therapy', *FEBS Journal*, vol. 280, no. 17, pp. 4281–4293, Sept. 2013, doi: 10.1111/febs.12273

[92]

Peter S. Zammit, 'Muscle satellite cells adopt divergent fates: a mechanism for self-renewal?', *The Journal of Cell Biology*, vol. 166, no. 3, 2004, doi: 10.1083/jcb.200312007. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2172269/>

[93]

L. Boldrin and J. E. Morgan, 'Activating muscle stem cells: therapeutic potential in muscle diseases', *Current Opinion in Neurology*, vol. 20, no. 5, pp. 577–582, Oct. 2007, doi: 10.1097/WCO.0b013e3282ef5919

[94]

L. Boldrin, P. S. Zammit, and J. E. Morgan, 'Satellite cells from dystrophic muscle retain regenerative capacity', *Stem Cell Research*, vol. 14, no. 1, pp. 20–29, Jan. 2015, doi: 10.1016/j.scr.2014.10.007

[95]

J. Ross et al., 'Defects in Glycosylation Impair Satellite Stem Cell Function and Niche Composition in the Muscles of the Dystrophic Large Mouse', *STEM CELLS*, vol. 30, no. 10, pp. 2330–2341, Oct. 2012, doi: 10.1002/stem.1197

[96]

G. Ravenscroft, M. R. Davis, P. Lamont, A. Forrest, and N. G. Laing, 'New era in genetics of early-onset muscle disease: Breakthroughs and challenges', *Seminars in Cell & Developmental Biology*, vol. 64, pp. 160–170, Apr. 2017, doi: 10.1016/j.semcdb.2016.08.002

[97]

G. Ravenscroft, N. G. Laing, and C. G. Bönnemann, 'Pathophysiological concepts in the congenital myopathies: blurring the boundaries, sharpening the focus', *Brain*, vol. 138, no. 2, pp. 246–268, Feb. 2015, doi: 10.1093/brain/awu368

[98]

K. N. North et al., 'Approach to the diagnosis of congenital myopathies', *Neuromuscular Disorders*, vol. 24, no. 2, pp. 97–116, Feb. 2014, doi: 10.1016/j.nmd.2013.11.003

[99]

S. Quijano-Roy, R. Y. Carlier, and D. Fischer, 'Muscle Imaging in Congenital Myopathies', *Seminars in Pediatric Neurology*, vol. 18, no. 4, pp. 221–229, Dec. 2011, doi: 10.1016/j.spen.2011.10.003

[100]

Kimberly Amburgey, 'A natural history study of X-linked myotubular myopathy', *Neurology*, vol. 89, no. 13, 2017, doi: 10.1212/WNL.0000000000004415. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649758/>

[101]

Irene Colombo, 'Congenital myopathies: Natural history of a large pediatric cohort', *Neurology*, vol. 84, no. 1, 2015, doi: 10.1212/WNL.0000000000001110. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336094/>

[102]

'Guidance for Paediatric Physiotherapists - Managing Neuromuscular Disorders'. Available: <http://apcp.csp.org.uk/publications/guidance-paediatric-physiotherapists-managing-neuromuscular-disorders>

[103]

'APCP'. Available: <http://apcp.csp.org.uk/>

[104]

'Neuromuscular | Department of Neurology'. Available: <https://neuro.wustl.edu/education/fellowships/neuromuscular/>

[105]

'Muscular Dystrophy UK'. Available: <http://www.muscular dystrophyuk.org/>

[106]

C. E. M. Hollak and R. Lachmann, Eds, *Inherited metabolic disease in adults: a clinical guide*. [New York]: Oxford University Press, 2016. Available: <http://dx.doi.org/10.1093/med/9780199972135.001.0001>

[107]

J. M. Saudubray, M. R. Baumgartner, and J. Walter, Eds, *Inborn metabolic diseases: diagnosis and treatment*, 6th edition. Berlin: Springer, 2016.

[108]

G. F. Hoffmann, J. Zschocke, and W. L. Nyhan, *Inherited metabolic diseases: a clinical approach*. Heidelberg: Springer, 2009. Available: <http://dx.doi.org/10.1007/978-3-540-74723-9>

[109]

P. Machado, S. Brady, and M. G. Hanna, 'Update in inclusion body myositis', *Current Opinion in Rheumatology*, vol. 25, no. 6, pp. 763–771, Nov. 2013, doi: [10.1097/01.bor.0000434671.77891.9a](https://doi.org/10.1097/01.bor.0000434671.77891.9a)

[110]

P. M. Machado, M. M. Dimachkie, and R. J. Barohn, 'Sporadic inclusion body myositis', *Current Opinion in Neurology*, vol. 27, no. 5, pp. 591–598, Oct. 2014, doi: [10.1097/WCO.0000000000000129](https://doi.org/10.1097/WCO.0000000000000129)

[111]

P. M. Machado et al., 'Ongoing Developments in Sporadic Inclusion Body Myositis', *Current Rheumatology Reports*, vol. 16, no. 12, Dec. 2014, doi: [10.1007/s11926-014-0477-9](https://doi.org/10.1007/s11926-014-0477-9)

[112]

Mhoriam Ahmed, 'Targeting Protein Homeostasis in Sporadic Inclusion Body Myositis', *Science translational medicine*, vol. 8, no. 331, 2016, doi: 10.1126/scitranslmed.aad4583. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043094/>

[113]

M. Needham and F. L. Mastaglia, 'Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment', *Clinical Neurophysiology*, vol. 127, no. 3, pp. 1764–1773, Mar. 2016, doi: 10.1016/j.clinph.2015.12.011

[114]

R. Schröder and B. Schoser, 'Myofibrillar Myopathies: A Clinical and Myopathological Guide', *Brain Pathology*, vol. 19, no. 3, pp. 483–492, July 2009, doi: 10.1111/j.1750-3639.2009.00289.x

[115]

A. A. Amato and S. A. Greenberg, 'Inflammatory Myopathies', *CONTINUUM: Lifelong Learning in Neurology*, vol. 19, pp. 1615–1633, Dec. 2013, doi: 10.1212/01.CON.0000440662.26427.bd

[116]

M. Olivé, R. A. Kley, and L. G. Goldfarb, 'Myofibrillar myopathies', *Current Opinion in Neurology*, vol. 26, no. 5, pp. 527–535, Oct. 2013, doi: 10.1097/WCO.0b013e328364d6b1

[117]

P.-O. Carstens and J. Schmidt, 'Diagnosis, pathogenesis and treatment of myositis: recent advances', *Clinical & Experimental Immunology*, vol. 175, no. 3, pp. 349–358, Mar. 2014, doi: 10.1111/cei.12194

[118]

M. C. Dalakas, 'Inflammatory Muscle Diseases', *New England Journal of Medicine*, vol. 372,

no. 18, pp. 1734–1747, Apr. 2015, doi: 10.1056/NEJMra1402225

[119]

Great Britain. Audit Commission for Local Authorities and the National Health Service in England and Wales., What Seems to Be the Matter Communication (National Health Service Report). Stationery Office.

[120]

T. D. Bunker, 'An information leaflet for surgical patients.', *Annals of The Royal College of Surgeons of England*, vol. 65, no. 4, 1983, Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494353/>

[121]

'Toolkit for producing patient information.pdf'. Available: <https://www.uea.ac.uk/documents/246046/0/Toolkit+for+producing+patient+information.pdf>

[122]

M. Garner, Z. Ning, and J. Francis, 'A framework for the evaluation of patient information leaflets', *Health Expectations*, vol. 15, no. 3, pp. 283–294, Sept. 2012, doi: 10.1111/j.1369-7625.2011.00665.x

[123]

C F George, 'Prescription information leaflets: a pilot study in general practice.', *British Medical Journal (Clinical research ed.)*, vol. 287, no. 6400, 1983, Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1549423/>

[124]

K. G. Hollingsworth, P. L. de Sousa, V. Straub, and P. G. Carlier, 'Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: Consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1–2 October 2009, Paris, France', *Neuromuscular Disorders*, vol. 22, pp. S54–S67, Oct. 2012, doi: 10.1016/j.nmd.2012.06.005

[125]

M. P. Wattjes and D. Fischer, *Neuromuscular imaging*. New York: Springer, 2013. Available: <https://www.dawsonera.com/abstract/9781461465522>

[126]

S. C. Forbes et al., 'Magnetic Resonance Imaging and Spectroscopy Assessment of Lower Extremity Skeletal Muscles in Boys with Duchenne Muscular Dystrophy: A Multicenter Cross Sectional Study', *PLoS ONE*, vol. 9, no. 9, Sept. 2014, doi: 10.1371/journal.pone.0106435

[127]

G. H. Glover and E. Schneider, 'Three-point dixon technique for true water/fat decomposition with B0 inhomogeneity correction', *Magnetic Resonance in Medicine*, vol. 18, no. 2, pp. 371–383, Apr. 1991, doi: 10.1002/mrm.1910180211

[128]

R. J. Willcocks et al., 'Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort', *Annals of Neurology*, vol. 79, no. 4, pp. 535–547, Apr. 2016, doi: 10.1002/ana.24599

[129]

Jean-Yves Hogrel, 'Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy', *Neurology*, vol. 86, no. 11, 2016, doi: 10.1212/WNL.0000000000002464. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799716/>

[130]

'*American Journal of Roentgenology*', Available: <http://www.ajronline.org/doi/abs/10.2214/AJR.14.13755>

[131]

C. E. M. Hollak and R. Lachmann, Eds, *Inherited metabolic disease in adults: a clinical guide*. [New York]: Oxford University Press, 2016. Available: <http://dx.doi.org/10.1093/med/9780199972135.001.0001>

[132]

Nancy D Leslie, 'Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency', 2014, Available: <https://www.ncbi.nlm.nih.gov/books/NBK6816/>

[133]

Thomas Wieser, 'Carnitine Palmitoyltransferase II Deficiency', 2017, Available: <https://www.ncbi.nlm.nih.gov/books/NBK1253/>

[134]

Miguel A Martín, 'Glycogen Storage Disease Type V', 2014, Available: <https://www.ncbi.nlm.nih.gov/books/NBK1344/>

[135]

Nancy Leslie, 'Pompe Disease', 2017, Available: <https://www.ncbi.nlm.nih.gov/books/NBK1261/>

[136]

M. C. Ørngreen and J. Vissing, 'Treatment Opportunities in Patients With Metabolic Myopathies', *Current Treatment Options in Neurology*, vol. 19, no. 11, Nov. 2017, doi: 10.1007/s11940-017-0473-2

[137]

S. E. Olpin, E. Murphy, R. J. Kirk, R. W. Taylor, and R. Quinlivan, 'The investigation and management of metabolic myopathies', *Journal of Clinical Pathology*, vol. 68, no. 6, pp. 410-417, June 2015, doi: 10.1136/jclinpath-2014-202808

[138]

F. Muntoni, S. Torelli, and A. Ferlini, 'Dystrophin and mutations: one gene, several proteins, multiple phenotypes', *The Lancet Neurology*, vol. 2, no. 12, pp. 731–740, Dec. 2003, doi: 10.1016/S1474-4422(03)00585-4

[139]

K. Bushby et al., 'Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management', *The Lancet Neurology*, vol. 9, no. 1, pp. 77–93, Jan. 2010, doi: 10.1016/S1474-4422(09)70271-6

[140]

K. Bushby et al., 'Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care', *The Lancet Neurology*, vol. 9, no. 2, pp. 177–189, Feb. 2010, doi: 10.1016/S1474-4422(09)70272-8

[141]

V. Ricotti et al., 'Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy', *Journal of Neurology, Neurosurgery & Psychiatry*, vol. 84, no. 6, pp. 698–705, June 2013, doi: 10.1136/jnnp-2012-303902

[142]

N. M. Goemans et al., 'Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy', *New England Journal of Medicine*, vol. 364, no. 16, pp. 1513–1522, Apr. 2011, doi: 10.1056/NEJMoa1011367

[143]

J. R. Mendell et al., 'Eteplirsen for the treatment of Duchenne muscular dystrophy', *Annals of Neurology*, vol. 74, no. 5, pp. 637–647, Nov. 2013, doi: 10.1002/ana.23982

[144]

J. R. Mendell et al., 'Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy', *Annals of Neurology*, vol. 79, no. 2, pp. 257–271, Feb. 2016, doi: 10.1002/ana.24555

[145]

M. Kinali et al., 'Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study', *The Lancet Neurology*, vol. 8, no. 10, pp. 918–928, Oct. 2009, doi: 10.1016/S1474-4422(09)70211-X

[146]

S. Cirak et al., 'Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study', *The Lancet*, vol. 378, no. 9791, pp. 595–605, Aug. 2011, doi: 10.1016/S0140-6736(11)60756-3

[147]

K. Bushby et al., 'Ataluren treatment of patients with nonsense mutation dystrophinopathy', *Muscle & Nerve*, vol. 50, no. 4, pp. 477–487, Oct. 2014, doi: 10.1002/mus.24332

[148]

'Victorian Department of Health / University of Melbourne'. Available: <https://www2.health.vic.gov.au/>

[149]

'Best Practice in Memory Services: Learning from across England'. Available: <https://www.england.nhs.uk/wp-content/uploads/2014/12/memory-clinics-final.pdf>

[150]

E. Matthews et al., 'The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment', *Brain*, vol. 133, no. 1, pp. 9–22, Jan. 2010, doi: 10.1093/brain/awp294

[151]

S. L. Venance et al., 'The primary periodic paralyses: diagnosis, pathogenesis and

treatment', *Brain*, vol. 129, no. 1, pp. 8–17, Jan. 2006, doi: 10.1093/brain/awh639

[152]

S. C. Cannon, 'Channelopathies of Skeletal Muscle Excitability', in *Comprehensive Physiology*, R. Terjung, Ed., Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011, pp. 761–790. doi: 10.1002/cphy.c140062. Available: <http://doi.wiley.com/10.1002/cphy.c140062>

[153]

S. V. Tan et al., 'Refined exercise testing can aid dna-based diagnosis in muscle channelopathies', *Annals of Neurology*, vol. 69, no. 2, pp. 328–340, Feb. 2011, doi: 10.1002/ana.22238

[154]

L. Sharp and J. R. Trivedi, 'Treatment and Management of Neuromuscular Channelopathies', *Current Treatment Options in Neurology*, vol. 16, no. 10, Oct. 2014, doi: 10.1007/s11940-014-0313-6

[155]

S. Paganoni and A. Amato, 'Electrodiagnostic Evaluation of Myopathies', *Physical Medicine and Rehabilitation Clinics of North America*, vol. 24, no. 1, pp. 193–207, Feb. 2013, doi: 10.1016/j.pmr.2012.08.017

[156]

A. Fuglsang-Frederiksen, 'The role of different EMG methods in evaluating myopathy', *Clinical Neurophysiology*, vol. 117, no. 6, pp. 1173–1189, June 2006, doi: 10.1016/j.clinph.2005.12.018

[157]

A. Ferlini, C. Scotton, and G. Novelli, 'Biomarkers in Rare Diseases', *Public Health Genomics*, vol. 16, no. 6, pp. 313–321, 2013, doi: 10.1159/000355938

[158]

Boers, M (Boers, M); Brooks, P (Brooks, P); Strand, CV (Strand, CV); Tugwell, P (Tugwell, P), 'The OMERACT filter for outcome measures in rheumatology', JOURNAL OF RHEUMATOLOGY JOURNAL OF RHEUMATOLOGY, vol. 25, no. 2, pp. 198–199, 1998, Available: <https://contentstore.cla.co.uk/secure/link?id=caecd7db-09ea-e611-80c9-005056af4099>

[159]

R. A. Conwit, M. J. Bhanushali, J. D. Porter, P. Kaufmann, and L. Gutmann, 'Adding more muscle and nerve to clinical trials', Muscle & Nerve, vol. 44, no. 5, pp. 695–702, Nov. 2011, doi: 10.1002/mus.22130

[160]

'Qualification Process for Drug Development Tools'. Available: <https://www.fda.gov/downloads/drugs/guidances/ucm230597.pdf>

[161]

M. Ahmed et al., 'Targeting protein homeostasis in sporadic inclusion body myositis', Science Translational Medicine, vol. 8, no. 331, pp. 331ra41–331ra41, Mar. 2016, doi: 10.1126/scitranslmed.aad4583

[162]

A Cruz-Martínez, 'Single fiber electromyography (SFEMG) in mitochondrial diseases (MD)', Electromyography and clinical neurophysiology, 2004.

[163]

J. Hull et al., 'British Thoracic Society guideline for respiratory management of children with neuromuscular weakness', Thorax, vol. 67, no. Suppl 1, pp. i1–i40, July 2012, doi: 10.1136/thoraxjnl-2012-201964

[164]

'American Journal of Respiratory and Critical Care Medicine', Available: <http://www.atsjournals.org/doi/abs/10.1164/ajrccm.161.1.9901057>

[165]

S. Ward, 'Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia', *Thorax*, vol. 60, no. 12, pp. 1019–1024, Dec. 2005, doi: 10.1136/thx.2004.037424

[166]

'Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial', *The Lancet Neurology*, vol. 14, no. 9, pp. 883–892, Sept. 2015, doi: 10.1016/S1474-4422(15)00152-0

[167]

I. O. C. Woollacott and J. D. Rohrer, 'The clinical spectrum of sporadic and familial forms of frontotemporal dementia', *Journal of Neurochemistry*, vol. 138, pp. 6–31, Aug. 2016, doi: 10.1111/jnc.13654

[168]

E. Gordon, J. D. Rohrer, and N. C. Fox, 'Advances in neuroimaging in frontotemporal dementia', *Journal of Neurochemistry*, vol. 138, pp. 193–210, Aug. 2016, doi: 10.1111/jnc.13656

[169]

L. Li, W.-C. Xiong, and L. Mei, 'Neuromuscular Junction Formation, Aging, and Disorders', *Annual Review of Physiology*, vol. 80, no. 1, Feb. 2018, doi: 10.1146/annurev-physiol-022516-034255

[170]

N. Singhal and P. T. Martin, 'Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junction', *Developmental Neurobiology*, vol. 71, no. 11, pp. 982–1005, Nov. 2011, doi: 10.1002/dneu.20953

[171]

H. Nishimune et al., 'Laminins promote postsynaptic maturation by an autocrine mechanism at the neuromuscular junction', *The Journal of Cell Biology*, vol. 182, no. 6, pp. 1201–1215, Sept. 2008, doi: 10.1083/jcb.200805095

[172]

H. Nishimune, 'Active zones of mammalian neuromuscular junctions: formation, density, and aging', *Annals of the New York Academy of Sciences*, vol. 1274, no. 1, pp. 24–32, Dec. 2012, doi: 10.1111/j.1749-6632.2012.06836.x

[173]

R. Rudolf, M. M. Khan, S. Labeit, and M. R. Deschenes, 'Degeneration of Neuromuscular Junction in Age and Dystrophy', *Frontiers in Aging Neuroscience*, vol. 6, May 2014, doi: 10.3389/fnagi.2014.00099

[174]

M. Otto et al., 'Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS', *Amyotrophic Lateral Sclerosis*, vol. 13, no. 1, pp. 1–10, Jan. 2012, doi: 10.3109/17482968.2011.627589

[175]

N. G. Simon et al., 'Quantifying disease progression in amyotrophic lateral sclerosis', *Annals of Neurology*, vol. 76, no. 5, pp. 643–657, Nov. 2014, doi: 10.1002/ana.24273

[176]

C.-H. Lu et al., 'Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis', *Neurology*, vol. 84, no. 22, pp. 2247–2257, June 2015, doi: 10.1212/WNL.0000000000001642

[177]

D. Caballero-Hernandez et al., 'The "Omics" of Amyotrophic Lateral Sclerosis', *Trends in Molecular Medicine*, vol. 22, no. 1, pp. 53–67, Jan. 2016, doi: 10.1016/j.molmed.2015.11.001

[178]

Michael Benatar, 'ALS Biomarkers for Therapy Development: State of the Field & Future Directions', *Muscle & nerve*, vol. 53, no. 2, 2016, doi: 10.1002/mus.24979. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718795/>

[179]

Ulf Andreasson, 'Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders', *Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring*, vol. 3, 2016, doi: 10.1016/j.dadm.2016.05.005. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941042/>

[180]

J.-H. Kang et al., 'The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans', *Alzheimer's & Dementia*, vol. 11, no. 7, pp. 772–791, July 2015, doi: 10.1016/j.jalz.2015.05.003

[181]

A. Al-Chalabi, L. H. van den Berg, and J. Veldink, 'Gene discovery in amyotrophic lateral sclerosis: implications for clinical management', *Nature Reviews Neurology*, vol. 13, no. 2, pp. 96–104, Dec. 2016, doi: 10.1038/nrneurol.2016.182

[182]

M. T. Carrì, N. D'Ambrosi, and M. Cozzolino, 'Pathways to mitochondrial dysfunction in ALS pathogenesis', *Biochemical and Biophysical Research Communications*, vol. 483, no. 4, pp. 1187–1193, Feb. 2017, doi: 10.1016/j.bbrc.2016.07.055

[183]

G. Lin, D. Mao, and H. J. Bellen, 'Amyotrophic Lateral Sclerosis Pathogenesis Converges on Defects in Protein Homeostasis Associated with TDP-43 Mislocalization and Proteasome-Mediated Degradation Overload', in *Fly Models of Human Diseases*, Elsevier, 2017, pp. 111–171. doi: 10.1016/bs.ctdb.2016.07.004. Available: <http://linkinghub.elsevier.com/retrieve/pii/S0070215316301454>

[184]

Z. Monahan, F. Shewmaker, and U. B. Pandey, 'Stress granules at the intersection of autophagy and ALS', *Brain Research*, vol. 1649, pp. 189–200, Oct. 2016, doi: 10.1016/j.brainres.2016.05.022

[185]

C. Ruegsegger and S. Saxena, 'Proteostasis impairment in ALS', *Brain Research*, vol. 1648, pp. 571–579, Oct. 2016, doi: 10.1016/j.brainres.2016.03.032

[186]

A. E. Renton, A. Chiò, and B. J. Traynor, 'State of play in amyotrophic lateral sclerosis genetics', *Nature Neuroscience*, vol. 17, no. 1, pp. 17–23, Jan. 2014, doi: 10.1038/nn.3584

[187]

T. M. Jessell, 'Neuronal specification in the spinal cord: inductive signals and transcriptional codes', *Nature Reviews Genetics*, vol. 1, no. 1, pp. 20–29, Oct. 2000, doi: 10.1038/35049541

[188]

R. Harland, 'Neural induction', *Current Opinion in Genetics & Development*, vol. 10, no. 4, pp. 357–362, Aug. 2000, doi: 10.1016/S0959-437X(00)00096-4

[189]

J. S. Dasen and T. M. Jessell, 'Chapter Six Hox Networks and the Origins of Motor Neuron Diversity', in *Hox Genes*, Elsevier, 2009, pp. 169–200. doi: 10.1016/S0070-2153(09)88006-X. Available: <http://linkinghub.elsevier.com/retrieve/pii/S007021530988006X>

[190]

D. Bonanomi and S. L. Pfaff, 'Motor Axon Pathfinding', *Cold Spring Harbor Perspectives in Biology*, vol. 2, no. 3, pp. a001735–a001735, Mar. 2010, doi: 10.1101/cshperspect.a001735

[191]

H. Darabid, A. P. Perez-Gonzalez, and R. Robitaille, 'Neuromuscular synaptogenesis: coordinating partners with multiple functions', *Nature Reviews Neuroscience*, vol. 15, no. 11, pp. 703–718, Nov. 2014, doi: 10.1038/nrn3821

[192]

K. C. Kanning, A. Kaplan, and C. E. Henderson, 'Motor Neuron Diversity in Development and Disease', *Annual Review of Neuroscience*, vol. 33, no. 1, pp. 409–440, June 2010, doi: 10.1146/annurev.neuro.051508.135722

[193]

D. R. Ladle, E. Pecho-Vrieseling, and S. Arber, 'Assembly of Motor Circuits in the Spinal Cord: Driven to Function by Genetic and Experience-Dependent Mechanisms', *Neuron*, vol. 56, no. 2, pp. 270–283, Oct. 2007, doi: 10.1016/j.neuron.2007.09.026

[194]

Robert M. Brownstone, 'Spinal interneurons providing input to the final common path during locomotion', *Progress in brain research*, vol. 187, 2010, doi: 10.1016/B978-0-444-53613-6.00006-X. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150186/>

[195]

E. O'Connor et al., 'Clinical and research strategies for limb-girdle congenital myasthenic syndromes', *Annals of the New York Academy of Sciences*, Jan. 2018, doi: 10.1111/nyas.13520

[196]

Andrew G. Engel, 'Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment', *The Lancet. Neurology*, vol. 14, no. 4, 2015, doi: 10.1016/S1474-4422(14)70201-7. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520251/>

[197]

P. M. R. Cruz, J. Palace, and D. Beeson, 'Congenital myasthenic syndromes and the neuromuscular junction', *Current Opinion in Neurology*, vol. 27, no. 5, pp. 566–575, Oct. 2014, doi: 10.1097/WCO.000000000000134

[198]

P. M. Rodríguez Cruz, J. Palace, and D. Beeson, 'Inherited disorders of the neuromuscular junction: an update', *Journal of Neurology*, vol. 261, no. 11, pp. 2234–2243, Nov. 2014, doi: 10.1007/s00415-014-7520-7

[199]

K. Belaya et al., 'Mutations in *CHCHD10* cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies', *Brain*, vol. 138, no. 9, pp. 2493–2504, Sept. 2015, doi: 10.1093/brain/awv185

[200]

P. M. Rodríguez Cruz et al., 'Congenital myopathies with secondary neuromuscular transmission defects; A case report and review of the literature', *Neuromuscular Disorders*, vol. 24, no. 12, pp. 1103–1110, Dec. 2014, doi: 10.1016/j.nmd.2014.07.005

[201]

S. J. Crisp, D. M. Kullmann, and A. Vincent, 'Autoimmune synaptopathies', *Nature Reviews Neuroscience*, vol. 17, no. 2, pp. 103–117, Feb. 2016, doi: 10.1038/nrn.2015.27

[202]

N. E. Gilhus, 'Myasthenia Gravis', *New England Journal of Medicine*, vol. 375, no. 26, pp. 2570–2581, Dec. 2016, doi: 10.1056/NEJMra1602678

[203]

Matthew N Meriggioli, 'Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity', *Lancet neurology*, vol. 8, no. 5, 2009, doi: 10.1016/S1474-4422(09)70063-8. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730933/>

[204]

J. Spillane, D. J. Beeson, and D. M. Kullmann, 'Myasthenia and related disorders of the neuromuscular junction', *Journal of Neurology, Neurosurgery & Psychiatry*, vol. 81, no. 8, pp. 850–857, Aug. 2010, doi: 10.1136/jnnp.2008.169367

[205]

Orrell, Richard WBarclay, Chris, 'Diagnosis and management of motor neurone disease', *Practitioner*, vol. 260, pp. 17–21, Available: <https://search.proquest.com/docview/1844334383?OpenUrlRefId=info:xri/sid:primo&aaccountid=14511>

[206]

S. Morgan and R. W. Orrell, 'Pathogenesis of amyotrophic lateral sclerosis', *British Medical Bulletin*, vol. 119, no. 1, pp. 87–98, Sept. 2016, doi: 10.1093/bmb/ldw026

[207]

G. Fuller and M. Manford, *Neurology: an illustrated colour text*, 3rd ed. Edinburgh: Churchill Livingstone, 2010. Available: <https://www.dawsonera.com/guard/protected/dawson.jsp?name=https://shib-idp.ucl.ac.uk/shibboleth&dest=http://www.dawsonera.com/depp/reader/protected/external/AbstractView/S9780702048883>

[208]

P. Couratier, P. Corcia, G. Lautrette, M. Nicol, P.-M. Preux, and B. Marin, 'Epidemiology of amyotrophic lateral sclerosis: A review of literature', *Revue Neurologique*, vol. 172, no. 1, pp. 37–45, Jan. 2016, doi: 10.1016/j.neurol.2015.11.002

[209]

'Motor neurone disease: assessment and management | Guidance and guidelines | NICE', Available: <https://www.nice.org.uk/guidance/ng42>

[210]

A. Vincent, 'Timeline: Unravelling the pathogenesis of myasthenia gravis', *Nature Reviews*

Immunology, vol. 2, no. 10, pp. 797–804, Oct. 2002, doi: 10.1038/nri916

[211]

Leslie Jacobson, 'Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice', *Journal of Clinical Investigation*, vol. 103, no. 7, 1999, doi: 10.1172/JCI5943. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC408264/>

[212]

W. Hoch, J. McConville, S. Helms, J. Newsom-Davis, A. Melms, and A. Vincent, 'Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies', *Nature Medicine*, vol. 7, no. 3, pp. 365–368, Mar. 2001, doi: 10.1038/85520

[213]

I. Koneczny, J. Cossins, and A. Vincent, 'The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis', *Journal of Anatomy*, vol. 224, no. 1, pp. 29–35, Jan. 2014, doi: 10.1111/joa.12034

[214]

S. Viegas et al., 'Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects', *Experimental Neurology*, vol. 234, no. 2, pp. 506–512, Apr. 2012, doi: 10.1016/j.expneurol.2012.01.025

[215]

I. Koneczny, J. Cossins, P. Waters, D. Beeson, and A. Vincent, 'MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters', *PLoS ONE*, vol. 8, no. 11, Nov. 2013, doi: 10.1371/journal.pone.0080695

[216]

S. J. Crisp, D. M. Kullmann, and A. Vincent, 'Autoimmune synaptopathies', *Nature Reviews Neuroscience*, vol. 17, no. 2, pp. 103–117, Feb. 2016, doi: 10.1038/nrn.2015.27

[217]

Beryl B. Cummings, 'Improving genetic diagnosis in Mendelian disease with transcriptome sequencing', *Science translational medicine*, vol. 9, no. 386, 2017, doi: 10.1126/scitranslmed.aal5209. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548421/>

[218]

D. Schofield et al., 'Cost-effectiveness of massively parallel sequencing for diagnosis of paediatric muscle diseases', *npj Genomic Medicine*, vol. 2, no. 1, Dec. 2017, doi: 10.1038/s41525-017-0006-7

[219]

G. L. O'Grady et al., 'Diagnosis and etiology of congenital muscular dystrophy: We are halfway there', *Annals of Neurology*, vol. 80, no. 1, pp. 101–111, July 2016, doi: 10.1002/ana.24687

[220]

C. G. Bönnemann et al., 'Diagnostic approach to the congenital muscular dystrophies', *Neuromuscular Disorders*, vol. 24, no. 4, pp. 289–311, Apr. 2014, doi: 10.1016/j.nmd.2013.12.011

[221]

K. N. North et al., 'Approach to the diagnosis of congenital myopathies', *Neuromuscular Disorders*, vol. 24, no. 2, pp. 97–116, Feb. 2014, doi: 10.1016/j.nmd.2013.11.003

[222]

M. P. Menezes and K. N. North, 'Inherited neuromuscular disorders: Pathway to diagnosis', *Journal of Paediatrics and Child Health*, vol. 48, no. 6, pp. 458–465, June 2012, doi: 10.1111/j.1440-1754.2011.02210.x

[223]

'Milestones timeline : Nature Milestones in DNA'. Available:
<https://www.nature.com/milestones/miledna/timeline.html>

[224]

M. L. Metzker, 'Sequencing technologies — the next generation', *Nature Reviews Genetics*, vol. 11, no. 1, pp. 31–46, Jan. 2010, doi: 10.1038/nrg2626

[225]

Y. Yang et al., 'Clinical Whole-Exome Sequencing for the Diagnosis of Mendelian Disorders', *New England Journal of Medicine*, vol. 369, no. 16, pp. 1502–1511, Oct. 2013, doi: 10.1056/NEJMoa1306555

[226]

Y. Sun et al., 'Next-Generation Diagnostics: Gene Panel, Exome, or Whole Genome?', *Human Mutation*, vol. 36, no. 6, pp. 648–655, June 2015, doi: 10.1002/humu.22783

[227]

R. Ghaoui et al., 'Use of Whole-Exome Sequencing for Diagnosis of Limb-Girdle Muscular Dystrophy', *JAMA Neurology*, vol. 72, no. 12, Dec. 2015, doi: 10.1001/jamaneurol.2015.2274

[228]

S. Richards et al., 'Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology', *Genetics in Medicine*, vol. 17, no. 5, pp. 405–423, May 2015, doi: 10.1038/gim.2015.30

[229]

Gabrielle Natalie Samuel, 'The UK's 100,000 Genomes Project: manifesting policymakers' expectations', *New Genetics and Society*, vol. 36, no. 4, 2017, doi: 10.1080/14636778.2017.1370671. Available:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706982/>

[230]

G. N. Samuel and B. Farsides, 'Public trust and "ethics review" as a commodity: the case of Genomics England Limited and the UK's 100,000 genomes project', *Medicine, Health Care and Philosophy*, Oct. 2017, doi: 10.1007/s11019-017-9810-1

[231]

A. G. Vaithinathan and V. Asokan, 'Public health and precision medicine share a goal', *Journal of Evidence-Based Medicine*, vol. 10, no. 2, pp. 76–80, May 2017, doi: 10.1111/jebm.12239

[232]

B. H. Griffin, L. S. Chitty, and M. Bitner-Glindzicz, 'The 100 000 Genomes Project: What it means for paediatrics', *Archives of disease in childhood - Education & practice edition*, vol. 102, no. 2, pp. 105–107, Apr. 2017, doi: 10.1136/archdischild-2016-311029

[233]

M. M. Evers, L. J. A. Toonen, and W. M. C. van Roon-Mom, 'Antisense oligonucleotides in therapy for neurodegenerative disorders', *Advanced Drug Delivery Reviews*, vol. 87, pp. 90–103, June 2015, doi: 10.1016/j.addr.2015.03.008

[234]

Karin E. Lundin, 'Oligonucleotide Therapies: The Past and the Present', *Human Gene Therapy*, vol. 26, no. 8, 2015, doi: 10.1089/hum.2015.070. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554547/>

[235]

O. Khorkova and C. Wahlestedt, 'Oligonucleotide therapies for disorders of the nervous system', *Nature Biotechnology*, vol. 35, no. 3, pp. 249–263, Mar. 2017, doi: 10.1038/nbt.3784

[236]

A. Aartsma-Rus, 'Overview on AON Design', in *Exon Skipping*, A. Aartsma-Rus, Ed., Totowa, NJ: Humana Press, 2012, pp. 117–129. doi: 10.1007/978-1-61779-767-5_8. Available:

http://link.springer.com/10.1007/978-1-61779-767-5_8

[237]

A. M. Rossor, M. M. Reilly, and J. N. Sleight, 'Antisense oligonucleotides and other genetic therapies made simple', *Practical Neurology*, Feb. 2018, doi: 10.1136/practneurol-2017-001764

[238]

N. Wood, *Neurogenetics*. Cambridge: Cambridge University Press, 2012. doi: 10.1017/CBO9781139087711. Available: <http://ebooks.cambridge.org/ref/id/CBO9781139087711>

[239]

C. Clarke, R. Howard, M. Rossor, and S. Shorvon, Eds, *Neurology*. Chichester, UK: John Wiley & Sons, Ltd, 2016. doi: 10.1002/9781118486160. Available: <http://doi.wiley.com/10.1002/9781118486160>

[240]

'OMIM - Online Mendelian Inheritance in Man'. Available: <https://www.omim.org/>

[241]

L. Teboul, Y. Héroult, C. Smith, and B. Whitelaw, 'Introduction to Mammalian Genome Special Issue: Genome Editing', *Mammalian Genome*, vol. 28, no. 7–8, pp. 235–236, Aug. 2017, doi: 10.1007/s00335-017-9708-5

[242]

A. Fernández, S. Josa, and L. Montoliu, 'A history of genome editing in mammals', *Mammalian Genome*, vol. 28, no. 7–8, pp. 237–246, Aug. 2017, doi: 10.1007/s00335-017-9699-2

[243]

Marie-Christine Birling, 'Modeling human disease in rodents by CRISPR/Cas9 genome editing', *Mammalian Genome*, vol. 28, no. 7, 2017, doi: 10.1007/s00335-017-9703-x. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569124/>

[244]

A. Greenfield, 'Editing mammalian genomes: ethical considerations', *Mammalian Genome*, vol. 28, no. 7–8, pp. 388–393, Aug. 2017, doi: 10.1007/s00335-017-9702-y

[245]

'Addgene: CRISPR Guide'. Available: <https://www.addgene.org/crispr/guide/>

[246]

'MGI-Mouse Genome Informatics -The international database resource for the laboratory mouse'. Available: <http://www.informatics.jax.org/>

[247]

A. M. Rossor, P. J. Tomaselli, and M. M. Reilly, 'Recent advances in the genetic neuropathies', *Current Opinion in Neurology*, Sept. 2016, doi: 10.1097/WCO.0000000000000373

[248]

A. M. Rossor, M. R. B. Evans, and M. M. Reilly, 'A practical approach to the genetic neuropathies', *Practical Neurology*, vol. 15, no. 3, pp. 187–198, June 2015, doi: 10.1136/practneurol-2015-001095